JRoon71
5 minutes ago
Kiwi, I do not know enough about drug trial requirements to know if this is the case. But even if it is, it does not mean that a BP is not willing to buy Amarin and assume the responsibility of running the trials themselves, post-acquisition. If there is a strong enough case for the new formulation,